Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

e on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

Non GAAP Measures

This press release contains financial measures not prepared in accordance with US GAAP. These measures are referred to as "non GAAP" measures and include Non GAAP operating income, Non GAAP net income, Non GAAP diluted earnings per ordinary share, Non GAAP diluted earnings per ADS and effective tax rate on Non GAAP income. These non GAAP measures exclude the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business.

These non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of the Company's performance to historical results and to competitors' results. These measures are also considered by Shire's Remuneration Committee in assessing the performance and compensation of employees, including its executive directors.

The non GAAP measures are presented in this press release as the Company's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, the Company's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many one-time, infrequent or non-cash items that the Company's management believe are not indicative of the core performance of the bus
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... December 14 , - ... of,Women With Rheumatoid Arthritis in Seven Major Industrialized Countries , ... with rheumatoid arthritis say their disease, ... - Women living with rheumatoid arthritis find shopping for ... cards and wrapping presents most, ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a pre-clinical ... cancer, staph aureus, and cardiovascular disease announces a ... today that Rosalie Dunn, Ph.D., has joined Gwathmey ... over 28 years of experience working with small ... joining Gwathmey, Dr. Dunn managed multimillion dollar portfolios ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... the second month in a row,the capital markets succumbed to ... of the month the Dow dropped over 300 points after,oil ... Amid these,fears, biotech was dragged down with the Burrill Biotech ... the Dow, which closed down,3%., "The biotech sector started ...
... COPENHAGEN, Denmark and LELYSTAD, Netherlands, March 3, Genmab ... of a research collaboration aimed at identifying fully,human ... those that are difficult to address using,commonly available ... antibodies. These difficulties can for example be due ...
... Pathology LIS Interface to Digital Pathology Information ... ... 3 IMPAC Medical,Systems, Inc. (IMPAC), an Elekta company and ... Aperio Technologies, (Aperio) a global leader in digital pathology for,the ...
Other Biology Technology:Biotech Drops Amid Tough Markets in February 2Biotech Drops Amid Tough Markets in February 3Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 2IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 3
(Date:12/14/2009)... The most comprehensive study to date of the ... appendages may provide important clues to how similar regeneration ... the School of Science at Indiana University-Purdue University Indianapolis ... amputated limbs of axolotls, a type of salamander that ... any level of amputation, with the hope that this ...
(Date:12/14/2009)... A team of researchers from the Astrobiology Centre (INTA-CSIC) ... considered essential to the formation of the most basic ... blue. In order to carry out this study, published ... scientists recreated the chemical conditions of the early Earth. ... dissolved in ammoniac solutions it produces hydrogen cyanide, a ...
(Date:12/14/2009)... support of the United Nations Framework Convention on ... Environment Agency hosted the ,Bend the Trend, event ... networking platform and premiere the screening of the ... Atlas of Europe, a joint project of the ... (UNEP) and ESA, is a series of short ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Prussian blue linked to the origin of life 2'Environmental Atlas of Europe' unveiled at COP15 2Mountain Home Helps Companies Battle Tough Economic Times by Offering Free Lean Six Sigma Training 58111 1Mountain Home Helps Companies Battle Tough Economic Times by Offering Free Lean Six Sigma Training 58111 2Webinar Series Launches for Eye Care Personnel 58108 1Webinar Series Launches for Eye Care Personnel 58108 2Webinar Series Launches for Eye Care Personnel 58108 3Webinar Series Launches for Eye Care Personnel 58108 4NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 1NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 2
... Savant's latest SpeedVac Concentrator, the SPD series ... a new modern twist., The SPD121P SpeedVac ... gauge for optimizing runs; preventing samples from ... stopped at the end-users preset level., Standard ...
... hybridization ovens are designed to create the ideal ... control (ambient to 99.9C) , Variable speed ... of samples, whether it be for washing or ... the current temperature inside the chamber, ,is situated ...
... is the latest edition to the famous ... an extra large diameter exhaust port for ... panel allows precise setting and control of ... handling large quantities and samples , ...
... Thermo Savant SpeedVac™ Concentrators set the standard for ... SC210A SpeedVac with large chamber uses a combination ... multiple samples in a single run. , SC210A ... Chamber for long lasting chemical compatibility ...
Biology Products: